# A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

> **NCT03675581** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 17 (actual)

## Conditions studied

- Scleroderma, Systemic

## Interventions

- **DRUG:** Microgynon
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT03675581
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-08
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675581, "A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03675581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*